Could This Single Molecule Cure Alzheimer’s?

Editor Jeff Siegel isn’t saying psychedelics represent a “miracle cure,” but they're about the closest thing he’s ever seen, which is why he’s been loading up the boat since 2019. And you should be too. Because the psychedelics market is going to make a lot of people very, very rich — but only those who get in now, while these stocks are still trading at tremendous discounts. Editor Jeff Siegel isn’t saying psychedelics represent a “miracle cure,” but they're about the closest thing he’s ever seen, which is why he’s been loading up the boat since 2019. And you should be too. Because the psychedelics market is going to make a lot of people very, very rich — but only those who get in now, while these stocks are still trading at tremendous discounts. [Energy and Capital logo] Could This Single Molecule Cure Alzheimer’s? [Jeff Siegel Photo] By [Jeff Siegel]( Written Feb 04, 2021 My heart broke when I heard the news… One of my favorite singers of all time, and one of the nicest guys I’ve ever met, announced that he has Alzheimer’s. His name is Anthony Benedetto But you probably know him as Tony Bennett. Although Bennett had been a household name since the 1950s, I didn’t discover him until the 1980s, when he launched a comeback that appealed to the MTV generation. Gen X kids from across the globe were treated to a talent that ultimately turned many of us into jazz fans. I was certainly one of them. But it wasn’t until the early 2000s that I got the chance to meet Tony Bennett. He was playing at a theater where a good friend of mine worked as a sound engineer. I got to watch the sound check before the show, and later, as hundreds of fans stood in a line that wrapped around the building, I had the opportunity to spend a few minutes with Tony. I’m calling him that because he told me to call him Tony after I addressed him as Mr. Bennett. :) In any event, I have to tell you that he was one of the nicest, most down-to-earth people I’ve ever met. We talked music, food, and family. It was an absolute pleasure. So when I heard Tony had been stricken with Alzheimer’s, my stomach fell. My great-grandmother suffered from Alzheimer’s, and I know just how horrible this disease is. In fact, as an investor, I’ve always been eager to invest in companies that are seeking to find a cure for this terrible disease. 10X Bigger Than Amazon, Apple, or Google?? Amazon, Tesla, and Facebook... Along with the Army, Navy, Marine Corps, Airforce and Pentagon are all piling into a controversial new technology. According to the World Economic Forum, this new technology could be worth $12.7 trillion over the next few years... If you're looking to cash in on the next major tech trend...This is it. [Click here for the full story (#1 Tech named inside).]( Interestingly, one of the newest potential therapies for Alzheimer’s is one that uses LSD. A company called Eleusis is investigating the anti-inflammatory potential of psychedelics, specifically the application of subperceptual doses of LSD in halting the progression of Alzheimer’s disease. While plenty of folks still equate LSD with hippies and party drugs, the truth is LSD has been studied for decades as a potential treatment for all kinds of mental health and neurodegenerative diseases. But only recently has this molecule moved out of the shadows and into FDA clinical trials and Wall Street boardrooms. This Is a No-Brainer If you’re a regular reader of these pages, you know I’ve been very bullish on the psychedelics space. In fact, I’ve recommended seven psychedelics stocks to members of my Green Chip Stocks community. And they’re all doing very well. In fact, one in particular, a company called MindMed (OTCBB: MMEDF), has thus far delivered us gains in excess of 760%. And to be honest, we haven’t even scratched the surface on that one yet. For nearly two years now, I’ve immersed myself in this market. I’ve pored through the research, visited university chemistry labs where researchers are developing all kinds of various psychedelic molecules, and have done dozens of site visits to see this stuff for myself. In my nearly 30 years in finance, I can tell you without hesitation that I’ve never seen an industry so full of potential. When it comes to mental health treatments, neurodegenerative diseases, and brain trauma, there is little on the market today that works effectively. Yet the earliest research on these psychedelic medicines is showing success rates that make what’s currently on the market look like snake oil. Elon Musk Drops MASSIVE Bombshell The shrewd billionaire just made a VERY strange confession about the future of his electric car empire. The secret he reveals could also mint fortunes for smart, fast-moving investors. This has nothing to do with buying shares of Tesla. [Click here]( for the stunning details. Take the research study that Johns Hopkins University did a couple years ago, where researchers showed tremendous success in treating smoking addiction with psilocybin therapy. If you’re unfamiliar, psilocybin is the psychedelic compound produced by “magic mushrooms.” And in this Johns Hopkins study, researchers saw an 80% success rate, which is unheard of in the world of addiction treatment. The most "effective” smoking cessation therapy on the market today boasts a success rate of about 30%. Hardly a "success," to be sure. In addition to studies being conducted at Johns Hopkins, there are now about a dozen private and public companies actively conducting, or preparing to conduct, FDA clinical trials using psychedelic compounds to treat everything from anxiety and depression to PTSD and addiction to Alzheimer’s and Parkinson’s. I’m not saying psychedelics represent a “miracle cure,” but they're about the closest thing I’ve ever seen, which is why I’ve been loading up the boat since 2019. And you should be too. Because the bottom line is the psychedelics market is going to make a lot of people very, very rich — but only those who get in now, while these stocks are still trading at tremendous discounts. You can get access to a list of some of these companies [here](. I’ve also put together a short white paper on the psychedelics market, its potential value for investors, and, of course, some of the psychedelics companies that are just crushing it in the space. You can [check that out here](. To a new way of life and a new generation of wealth... [Jeff Siegel Signature] Jeff Siegel --------------------------------------------------------------- Place Your Bets on a Bigger and Safer Rally Than GameStop If there’s anything we’ve learned this past week, it’s to never underestimate an underdog. We all watched in awe as GameStop reached a share price of $400 last week, thanks to a mass of savvy traders on Reddit who gathered together to short squeeze hedge funders out of billions. Traders went nuts, but experts warned that the bubble could burst at any minute. And it did. Robinhood prohibited the purchasing of GameStop shares to “protect” its users from a volatile market just a few days after the rally began. We all know what was really going on: market manipulation at its finest. Hedge funds were declaring bankruptcy, while the little people were winning. But Wall Street decided that what took place should be illegal. So why not stick it to Wall Street by placing your bet on a smaller, more promising gaming company with a brighter future than GameStop? Not to mention, this is a safer investment than pouring money into a company that’s been in decline. If you are looking for something risky and volatile like what we saw in GameStop, then you can stop reading now. But if you want to get in on a solid tiny company while it’s still on the ground floor, then read on. [Click here for all of the details…]( Browse Our Archives [The Mob Takes Down Another Fool]( [Looking for the Next GameStop?]( [3 Takeaways From the GME Army's Short Squeeze on Wall Street]( [The Greatest Short Squeeze Ever Occurred in 1922]( [How President Biden Is Single-Handedly Saving the Oil Industry]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Energy and Capital](, Copyright © 2021, [Angel Publishing LLC](. All rights reserved. 3 E Read Street, Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Energy and Capital]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.